Erenumab-aooe

(Aimovig®)

Aimovig®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (subcutaneous; 70 mg/mL, 140 mg/mL)
Drug ClassCalcitonin gene-related peptide receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the preventive treatment of migraine in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Erenumab-aooe (Aimovig) is indicated for the preventive treatment of migraine in adults, demonstrating substantial efficacy in reducing monthly migraine days with dose-dependent responses observed.
  • A total of 26 studies were reviewed, providing insights into randomized clinical trials and real-world evidence assessing these preventive treatments on various populations including those with episodic migraine (EM), chronic migraine (CM), medication overuse headache (MOH), and drug-resistant cases.
  • Compared to other CGRP monoclonal antibodies such as eptinezumab, fremanezumab, and galcanezumab, Erenumab's performance was slightly lower in some metrics but outperformed others, particularly within real-world settings and specific subpopulations like those suffering from MOH.
  • The safety profile of erenumab is impressive, with adverse events being generally mild to moderate and significantly lower than traditional oral preventatives such as topiramate. Serious adverse events are rare across the board for this class of drugs.
  • Erenumab has shown consistent effectiveness across diverse patient populations, including patients with EM or CM, indicating broad applicability. It also shows potential as a valuable option for difficult-to-treat migraines where previous treatments have failed.
  • Subgroup analyses suggest consistent effectiveness and safety across genders, though more targeted research might be needed to fully understand any gender-specific responses or considerations related to the use of erenumab.
  • Comparative analysis suggests that while all CGRP MAbs are effective, there may be variations which could guide personalized treatment decisions based on individual patient suitability considering both efficacy and safety profiles.
  • Erenumab presents a favorable benefit-risk ratio when compared against established treatments like topiramate, marking it an advancement in prophylaxis against both episodic and chronic migraines due to its potent efficacy combined with superior tolerability profiles.

Product Monograph / Prescribing Information

Document TitleYearSource
Aimovig (erenumab-aooe) Prescribing Information.2023Amgen Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Reporting quality and risk of bias analysis of published RCTs assessing anti-CGRP monoclonal antibodies in Migraine Prophylaxis: a systematic review.2024Journal of Clinical Medicine
The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.2024Neurological Sciences
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis.2023Cephalalgia: International Headache Society
Erenumab efficacy in migraine headache prophylaxis: a systematic review.2023International Immunopharmacology
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials.2023Cephalalgia: International Headache Society
Efficacy and safety of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in preventing migraines: a systematic review.2023Cureus
Effectiveness of calcitonin gene-related peptide monoclonal antibodies in the prevention of migraine: a systematic review and meta-analysis of observational cohort studies.2023Clinical Drug Investigation
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. 2023Journal of Headache and Pain
Comparative efficacy and safety of five anti-calcitonin gene-related peptide agents for migraine prevention: a network meta-analysis.2023The Clinical Journal of Pain
Gender bias in clinical trials of biological agents for migraine: a systematic review. 2023PLoS One
Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis.2023The Journal of Headache and Pain
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. 2022The Journal of Headache and Pain
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.2022The Journal of Headache and Pain
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.2022European Journal of Medical Research
Different dosage regimens of erenumab for the treatment of migraine: a systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.2022Headache: The Journal of Head and Face Pain
Long-term safety and effectiveness of erenumab in patients with migraine: a systematic review and single-arm meta-analysis.2022Clinical Drug Investigation
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. 2021Expert Opinion on Drug Safety
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. 2021Frontiers in Pharmacology
Safety and tolerability evaluation of erenumab for the preventive treatment of migraine. 2021Expert Opinion on Drug Safety
Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. 2021Cephalalgia
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis.2021Clinical Neurology and Neurosurgery
Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene‑related peptide and its receptor for the prevention of chronic migraine: a network meta‑analysis of randomized controlled trials.2021Neurotherapeutics
Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta analysis.2021CNS Drugs
Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety.2019Drugs
Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials.2019Medicine
CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data.2019Cephalalgia

Clinical Practice Guidelines